Search Results
Your search for Colorectal matches 3239 pages
Showing 1301 - 1350Rates of Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer Doubled by Pembrolizumab
Upfront treatment with immunotherapy not only improved results in a subset of patients with metastatic colorectal cancer, it doubled the rates of median progression-free survival. These findings—the first of their kind—arose from the interim analysis of the randomized open-label phase III...
Conference Highlights From the ASCO20 Virtual Scientific Program
The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
FDA Approves Pembrolizumab for the First-Line Treatment of MSI-H/dMMR Colorectal Cancer
On June 29, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer. KEYNOTE-177 Approval was based on...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
Integrating Physical Activity Into Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Accumulating evidence suggests the benefits of physical activity through the cancer continuum....
Seattle Cancer Care Alliance Opens New Clinic Dedicated to Gastrointestinal Cancer Care
Seattle Cancer Care Alliance (SCCA) announced the opening of a Gastrointestinal (GI) Care Neighborhood, a new cancer clinic aimed at improving the experience for patients with GI cancers, which features dedicated GI-related cancer care services on one floor of SCCA’s South Lake Union campus. “We...
Survey Shows Young-Onset Colorectal Cancer May Be Overlooked in Exam Rooms
The Colorectal Cancer Alliance recently released findings from its latest survey of patients with young-onset colorectal cancer and survivors. The Never Too Young Survey shares the self-reported medical, psychosocial, and quality-of-life experiences of this often-overlooked population to better...
Improving Care for Women With Late-Stage Breast Cancer
The global toll of breast cancer on women is staggering. In 2018, nearly two million new breast cancer cases were diagnosed, an increase of more than 20% since 2008,1 and mortality rates have increased by 14%, bringing the annual number of deaths worldwide from the cancer to more than 611,625.2...
Expert Point of View: Michael S. Lee, MD, and Autumn McRee, MD
DESTINY-CRC01 study discussant, Michael S. Lee, MD, Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, called the findings “most promising” for the subsequent anti-HER2 treatment of HER2-positive metastatic colorectal cancer. The...
Trastuzumab Deruxtecan Shows Benefit in Refractory Colorectal Cancer
Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.1 T-DXd is an antibody-drug conjugate...
Young Adults With Cancer May Benefit From Germline Genetic Testing
According to the National Cancer Institute, each year, about 70,000 adolescents and young adults (AYA)—those between the ages of 15 and 39—are diagnosed with cancer. Evidence suggests that some cancers found in AYA patients may have unique genetic and biologic features. A study that investigated...
FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia
Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...
Cisplatin/Fluorouracil vs Carboplatin/Paclitaxel in Chemotherapy-Naive Patients With Advanced Anal Cancer
In an International Rare Cancers Initiative phase II trial (InterAAct) reported in the Journal of Clinical Oncology, Rao et al found that carboplatin/paclitaxel was associated with less serious toxicity and a trend toward improved overall survival vs cisplatin/fluorouracil in chemotherapy-naive...
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or...
Retrospective Study of Characteristics and Outcomes in Patients With Cancer Hospitalized With COVID-19 in Hubei
In a retrospective cohort study reported in The Lancet Oncology, Yang et al described clinical characteristics, outcomes, and risk factors for mortality in patients with cancer hospitalized with COVID-19 over a 2-month period in Hubei, China. Study Details The study included 205 patients with...
Stereotactic Ablative Radiotherapy for Oligometastatic Cancer: Long-Term Findings From the SABR-COMET Trial
In a long-term follow-up of the phase II SABR-COMET trial reported in the Journal of Clinical Oncology, David A. Palma, MD, PhD, and colleagues found that the addition of stereotactic ablative radiotherapy (SABR) to palliative standard-of-care treatment in patients with oligometastatic cancers...
Meta-analysis of Outcomes With Checkpoint Inhibitor Treatment in Advanced Microsatellite Instability–High Cancers
A meta-analysis of published studies of immune checkpoint inhibition for advanced microsatellite instability–high (MSI-H) cancers—published as a brief report in JAMA Oncology by Petrelli et al—found high activity of these therapies across tumor types and evaluated agents. Study Details The...
Study Finds Blood Test Detects Cancer and Tissue of Origin in Those With or Suspected to Have Cancer
A blood test based on cell-free DNA was able to detect cancer as well as the site of origin in patients with a clinical suspicion of cancer, according to results of the Circulating Cell-Free Genome Atlas (CCGA) study presented at the 2020 American Association for Cancer Research (AACR) Virtual...
Five New Recipients of NCCN Foundation Young Investigator Awards
The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation announced five new recipients for the 10th annual NCCN Foundation Young Investigator Awards Program. The honorees will receive up to $150,000 in funding to study ways to improve care and help find cures for people with...
Plenary Research From the ASCO20 Virtual Scientific Program: Part 1
This week, we’ll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer.
Study Finds Substantial Racial/Ethnic Disparities in Lost Earnings From Cancer Mortality
Disparities in cancer mortality rates between black and white Americans date back more than 60 years. Now, a study by the American Cancer Society comparing person-years of life lost and lost earnings due to premature cancer mortality by race/ethnicity has quantified the economic burden due to...
Renowned Researcher and Surgeon Helps to Transform Treatment of Breast Cancer
Although ‘paradigm shifts’ are frequently referenced in oncology, these are really few and far between. They occur when new data either partially invalidate previously accepted theory or are at complete odds with the existing paradigm. Moving away from the Halsted radical mastectomy, a standard of ...
Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).
Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease
Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite...
Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard chemotherapy did not significantly improve...
Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard chemotherapy, encorafenib plus cetuximab with or without binimetinib improved overall survival and objective response rate...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
Pembrolizumab Doubles Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer
For the first time, upfront treatment with immunotherapy has improved—in fact, doubled—median progression-free survival in a subset of patients with metastatic colorectal cancer. The findings are from the interim analysis of the randomized open-label phase III KEYNOTE-177 trial comparing the...
Milestone Memories: Conquer Cancer Researcher Searches for Colorectal Cancer Cures
On her wedding day, a father—who happens to have colorectal cancer—walks his daughter down the aisle. His oncologist, Rona Yaeger, MD, of Memorial Sloan Kettering Cancer Center, helped him mark this milestone. Currently, patients with BRAF-mutant colorectal cancers face a poor prognosis. Dr....
Roswell Park Investigators Study Immunotherapy Combination in Patients With Cancer Infected With COVID-19
A clinical trial investigating a two-drug immunotherapy combination will soon be available to patients with cancer infected with COVID-19 at Roswell Park Comprehensive Cancer Center in Buffalo. The U.S. Food and Drug Administration (FDA) has authorized clinical researchers at the center to conduct...
Selected Poster Presentations on Cancer Therapeutics and More
Although the live 2020 National Comprehensive Cancer Network (NCCN) Annual Conference was canceled, more than 100 posters scheduled for presentation are now available online, as part of the NCCN 2020 Virtual Annual Conference. The ASCO Post has summarized some of the clinical trial updates we found ...
Effectiveness of Different Severity Thresholds for Chemotherapy-Related Symptom Alerts
In a study reported in JCO Oncology Practice, Shi et al found that use of higher-than-currently-recommended severity thresholds for symptom alerts for patients receiving outpatient chemotherapy would result in failure to identify and treat many patients requiring clinical intervention for ...
Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
Half of Surveyed Cancer Researchers Report Their Work Is on Hold Due to the COVID-19 Pandemic
A survey of American Cancer Society grantees found that about half reported their cancer research has been halted as a result of the COVID-19 pandemic. The American Cancer Society reached out to all of its funded researchers to assess the state of their projects and collect information to guide...
Scott Kopetz, MD, PhD, FACP: Breakthroughs in Combination Therapy for Colorectal Cancer
Scott Kopetz, MD, PhD, FACP, works to improve outcomes for patients with colorectal cancer at The University of Texas MD Anderson Cancer Center. The trial: Single drugs aimed at inhibiting the BRAF gene have not been effective against BRAF-mutated colorectal cancers. To explore the effectiveness...
Encorafenib Combined With Cetuximab in Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer
On April 8, 2020, encorafenib was approved for use in combination with cetuximab for the treatment of previously treated adult patients with metastatic colorectal cancer with a BRAF V600E mutation detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 Encorafenib is not indicated...
Understanding Patient-Reported Outcomes in Cancer Trials: A Beginner’s Guide
Patient-reported outcomes are measures used in clinical trials to capture aspects of a patient’s health condition, reported directly by the patient, without introduction of bias from third parties. They are distinct from the physical toxicities reported by clinicians1 and are collected using a...
Actively Recruiting Clinical Trials Studying Cancer Prevention Measures
This Clinical Trials Resource Guide lists actively recruiting clinical trials evaluating strategies to improve cancer prevention measures, mostly through increased rates of screening. Some of the following trials also address cancer prevention through improving knowledge of tumor biomarkers,...
Reduction in Cancer Diagnoses in the Netherlands During the COVID-19 Pandemic
In a commentary published in The Lancet Oncology, Dinmohamed et al detailed a nationwide reduction in cancer diagnoses in the Netherlands in the several weeks following the first confirmed case of COVID-19 in the country compared with the several weeks preceding the first documented case. This...
Mortality Rate of Patients With Cancer and COVID-19 in a New York Hospital
Patients with cancer who were infected with COVID-19 were much more likely to die from the disease than those without cancer, according to research from physician-researchers at Montefiore Health System and Albert Einstein College of Medicine. Their findings were published by Mehta et al in Cancer...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing the risk of COVID-19...
Regorafenib Plus Nivolumab in Advanced Gastric and Colorectal Cancers
In a Japanese phase Ib/dose-expansion trial reported in the Journal of Clinical Oncology, Fukuoka et al found that the combination of regorafenib and nivolumab showed activity in patients with previously treated gastric cancer and colorectal cancer with microsatellite stable/mismatch...
AI Model Accurately Classifies Colorectal Polyps From Histopathologic Slides
An artificial intelligence (AI) model for automated classification of colorectal polyps could benefit cancer screening programs by improving efficiency, reproducibility, and accuracy, as well as reducing access barriers to pathology services. In a new study published by Wei et al in JAMA Network...
Treatment and Outcomes in Patients With Metastatic Colorectal Cancer in Washington State and Canada
In a study reported in JCO Oncology Practice, Todd A. Yezefski, MD, and colleagues found that the cost of first-line systemic therapy for metastatic colorectal cancer was higher in Western Washington state compared with British Columbia and that survival outcomes were similar. A stated by the...
Radiation and Chemoradiation Interruption and Noncompletion in Squamous Cell Anal Carcinoma
In a Canadian study reported in JAMA Oncology, Raphael et al found that interruption and noncompletion of definitive radiation and chemoradiation for patients with squamous cell anal carcinoma were common, and that failure to complete radiation and chemoradiation was associated with poorer...
Disruptions in Health Insurance Coverage and Cancer Care, Survival
A new study published by Yabroff et al in JNCI: The Journal of the National Cancer Institute found disruptions in health insurance coverage are common in the United States and are associated with poorer cancer care and survival. Disruptions can be caused by gaps in insurance coverage or transitions ...
Prognosis of Patients With Cancer and COVID-19: Outcomes From a Center in New York City
A group of clinicians from New York City sought to determine if patients with cancer and COVID-19 in the United States have a poor prognosis. In an article published as a pre-proof in Annals of Oncology, Miyashita et al analyzed the electronic medical records from the Mount Sinai Health System, and ...
PD-1 Inhibition in Mismatch Repair–Deficient/Microsatellite Instability–High Cancers Other Than Colorectal Cancer
Mismatch repair (MMR)-deficiency and consequently high DNA microsatellite instability (MSI-H) are associated with high tumor mutational burden. A high mutational load increases the potential number of neoantigens that can be presented by the tumor cell and recognized by host lymphocytes. Detection...
